The first instalment of two-part article looking at people behind the most important events and trends in pharma, biotech and wider world of healthcare in 2015.
For many years, orphan drugs for rare diseases have been a draw for pharma companies, offering high prices, swift regulatory reviews and often extended marketing exclusivi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.